ClearPoint Neuro, Inc. — Director's Dealing 2022

May 20, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ClearPoint Neuro, Inc. (CLPT)
CIK: 0001285550
Period of Report: 2022-05-13

Reporting Person: STIGALL L. JEREMY (GM, Biologics & Drug Delivery)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock		Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$16.71	2031-08-20	Common Stock (5875)		Direct

Footnotes

F1: Includes 22,563 shares of restricted stock, 19,274 shares of which are unvested as of the date of this filing.

F2: The option agreement provides that the option becomes exercisable twenty percent (20%) on the first anniversary of the option's grant date with the remaining eighty percent (80%) becoming exercisable in two equal annual installments on the second and third anniversaries, respectively, of the option's grant date. The option was granted on August 20, 2021.